Causes
Acute graft-versus-host disease occurs when immune cells (specifically T-cells) from the donor graft recognize proteins on the recipient's cells as foreign invaders. The donor cells activate and release inflammatory chemicals that damage the recipient's tissues. This process typically targets the skin, liver, and gastrointestinal tract because these tissues have high levels of the specific proteins that trigger the immune response. Underlying biological mechanisms involve a complex interaction where the chemotherapy or radiation used before the transplant damages tissues, releasing danger signals that further stimulate the donor immune cells to attack.

Risk Factors
Certain variables increase the likelihood of developing this condition. The most significant risk factor is the degree of mismatch between the donor's and recipient's tissue types, known as human leukocyte antigens (HLA). Other known risk factors include:

• Donor and Recipient Relationship: Unrelated donors generally pose a higher risk than matched sibling donors.
• Age: Older recipients and older donors are associated with higher rates of the disease.
• Gender Disparity: A female donor providing cells to a male recipient increases risk, especially if the donor has had previous pregnancies.
• Stem Cell Source: Peripheral blood stem cells may carry a higher risk compared to bone marrow or umbilical cord blood.
• Conditioning Intensity: High-intensity chemotherapy or radiation regimens used prior to transplant can increase tissue damage and subsequent risk.

Prevention
Preventive strategies are a standard part of the transplant process. Primary prevention involves selecting the best possible donor match and administering medications immediately after the transplant to suppress the immune system. Drugs such as methotrexate, tacrolimus, or cyclosporine are routinely given to inhibit donor T-cell activation. In some cases, T-cell depletion—removing T-cells from the graft before infusion—is performed, though this may impact the graft's ability to fight cancer cells. Lifestyle changes generally do not prevent the onset, as the cause is biological, but adhering to the prescribed medication regimen is critical for reducing risk.

Signs and Symptoms
Symptoms usually appear within the first 100 days after transplantation. The presentation varies in severity but classically involves a triad of organ systems. Symptoms may include:

• Skin: A red, maculopapular rash is often the first sign. It frequently begins on the palms of the hands, soles of the feet, or behind the ears and can spread to cover the entire body. In severe cases, the skin may blister or peel, resembling a severe burn.
• Gastrointestinal Tract: Patients may experience nausea, vomiting, loss of appetite, and abdominal pain. A hallmark symptom is voluminous, watery diarrhea, which may be greenish, mucoid, or contain blood.
• Liver: Involvement is often indicated by jaundice, which causes yellowing of the skin and whites of the eyes. Dark urine and abdominal tenderness in the upper right quadrant may also occur.

Diagnosis
Clinicians identify the condition based on the timing of symptoms relative to the transplant and the characteristic clinical presentation. Diagnostic tools include:

• Physical Exam: Doctors assess the extent of the skin rash and check for signs of liver or gut involvement.
• Laboratory Tests: Blood tests measure liver enzymes (bilirubin, alkaline phosphatase, AST, ALT) to evaluate liver function. Stool samples are analyzed to rule out infections like C. difficile or cytomegalovirus (CMV).
• Biopsy: This is the gold standard for confirmation. Small tissue samples from the skin, liver, or lining of the stomach or colon are taken and examined under a microscope to look for specific patterns of tissue damage and immune cell infiltration.

Differential Diagnosis
The condition is often confused with infections (viral, bacterial, or fungal), drug reactions (especially antibiotic rashes), or toxicity from the conditioning regimen (chemotherapy or radiation effects). Accurate diagnosis is essential because the treatment for immune-mediated disease differs vastly from treatment for infections.

Medical Treatment
The primary goal of treatment is to suppress the overactive donor immune cells without completely destroying the new immune system's ability to fight infection or cancer. Standard strategies include:

• Corticosteroids: High-dose steroids, such as methylprednisolone or prednisone, are the first-line treatment. They work rapidly to reduce systemic inflammation.
• Immunosuppressants: If steroids are ineffective, second-line therapies are introduced. These may include ruxolitinib, antithymocyte globulin, mycophenolate mofetil, or other targeted agents that block specific immune pathways.
• Topical Agents: Steroid creams may be applied directly to the skin for mild rashes to reduce local inflammation.

Supportive Care and Management
Managing symptoms and complications is as important as treating the underlying cause. Supportive measures include:

• Infection Prophylaxis: Because treatment suppresses the immune system, patients receive antiviral, antifungal, and antibacterial medications to prevent opportunistic infections.
• Nutritional Support: Patients with severe digestive symptoms may require bowel rest and intravenous nutrition (total parenteral nutrition) until the gut heals.
• Fluid Management: Aggressive fluid and electrolyte replacement is necessary to counter dehydration from severe diarrhea.
• Pain Management: Analgesics are used to control pain from skin blisters or abdominal cramping.

When to Seek Medical Care
Post-transplant patients are monitored closely, but immediate medical attention is required for certain changes. Seek care if:

• Rash Progression: A new rash appears or an existing rash spreads rapidly or becomes painful.
• Digestive Issues: You experience persistent nausea, vomiting, or diarrhea (especially if it prevents fluid intake).
• Jaundice: You notice yellowing of the skin or eyes or a change in urine color to dark brown.
• General Health: You develop a fever or signs of infection, as these can escalate quickly in immunosuppressed individuals.

Severity Grading
Acute graft-versus-host disease is graded on a scale from I to IV based on the extent of organ involvement. Grade I is generally mild, involving only a limited skin rash. Grade II is moderate, with more extensive skin involvement or mild liver/gut symptoms. Grades III and IV are severe and life-threatening, characterized by generalized skin blistering, high bilirubin levels indicating liver failure, or severe abdominal pain and diarrhea. The severity directly correlates with the difficulty of treatment and the ultimate outcome.

Prognosis and Disease Course
The prognosis depends heavily on the grade of the disease and how well the patient responds to initial steroid treatment. Patients with Grade I or II disease often respond well to therapy and have a favorable outlook. However, patients with Grade III or IV disease, or those whose condition does not improve with steroids (steroid-refractory), face higher risks. The condition is usually acute, occurring within the first few months, but can persist or recur. Successful treatment can lead to complete remission, although some patients may later develop the chronic form of the disease.

Complications and Long-Term Effects
The major risk associated with this condition is not just the organ damage itself, but the profound susceptibility to severe infections caused by both the disease and the intensive immunosuppressive treatments required to control it. Infection is a leading cause of mortality in severe cases. Long-term effects can include a transition to chronic graft-versus-host disease, which may cause lasting fibrosis and dysfunction in the skin, eyes, lungs, and other organs, impacting life expectancy and quality of life.

Daily Activities and Physical Health
Living with acute graft-versus-host disease requires significant adjustments. Physical limitations are common due to fatigue, muscle weakness from steroids, or discomfort from skin rashes and gastrointestinal symptoms. Daily routines often revolve around medication schedules and frequent medical appointments. Patients may need to follow strict dietary guidelines, such as a low-microbial diet, to protect the inflamed gut and prevent foodborne infections. Protecting the skin from sun exposure is also critical, as UV light can exacerbate the rash.

Mental and Emotional Well-being
The diagnosis can be emotionally taxing, causing anxiety and fear regarding transplant failure or relapse. The isolation required to prevent infection can lead to feelings of loneliness and depression. Coping strategies include staying connected with loved ones through technology, engaging in gentle hobbies, and seeking support from counselors specializing in cancer or transplant recovery.

Questions to Ask Your Healthcare Provider
Understanding your specific situation helps in managing the condition. Consider asking these questions:

• What grade is my condition, and what does that mean for my recovery timeline?
• What specific signs indicate that the treatment is working or failing?
• Are there any specific foods or activities I should strictly avoid right now?
• What are the side effects of the new medications I am taking?
• What can I do at home to help manage the itching or nausea?
• How does this diagnosis affect the long-term success of my transplant?

Q: Is acute graft-versus-host disease contagious?
A: No, it is not contagious. It is an internal immune reaction where donor cells attack the recipient's body, and it cannot be spread from person to person.

Q: Does getting this condition mean the transplant failed?
A: No, it does not mean the transplant failed. In fact, a mild case can be associated with a "graft-versus-leukemia" effect, where the donor cells also attack remaining cancer cells, potentially reducing the risk of cancer relapse.

Q: Can acute graft-versus-host disease be cured?
A: Yes, many cases are successfully treated and resolve completely. However, some cases may be resistant to treatment or may evolve into a chronic form that requires long-term management.

Q: Why does it happen even with a matched donor?
A: Even with a perfect HLA match, there are minor genetic differences between the donor and recipient that routine tests might not detect. These minor differences can still trigger the donor's immune system to recognize the recipient's tissues as foreign.

Q: How long does the treatment last?
A: The duration of treatment varies widely. It typically continues until symptoms resolve, after which medications are tapered slowly over weeks or months to prevent the condition from flaring up again.